MBZUAI researchers are refining AI techniques to improve cancer diagnosis for colorectal and breast cancer, both common in the Middle East. They are using "few-shot tissue image generation," in which AI generates data for training AI models to recognize lesions, addressing the challenge of limited training data. The developed framework improves the efficiency of radiologists in breast cancer diagnosis, leading to better detection of breast lesions and timely treatment interventions. Why it matters: These advancements in AI-aided diagnostics can lead to earlier and more accurate cancer detection, ultimately improving patient outcomes in the region and beyond.
A senior lecturer at the University of New South Wales discussed the use of AI to improve early prognosis and personalized treatment plans for neurodegenerative diseases, cardiovascular imaging and multiomics. The lecture highlighted the potential of AI algorithms to detect subtle changes at early stages through advanced multiomics techniques and medical imaging analysis. The speaker has expertise in analyzing medical images and has collaborated with medical professionals to develop AI tools for diagnosis of cancer, neurodegenerative disease, and heart disease. Why it matters: AI-driven prognosis and treatment planning promises earlier intervention and improved outcomes for challenging diseases in the region.
MBZUAI's first Ph.D. graduate, Numan Saeed, developed deep learning models to diagnose head and neck cancers using PET and CT scan imagery. His research focused on improving early detection and accurate localization of tumors, aiming to enhance diagnosis and prognosis. Early diagnosis can reduce mortality rates by up to 70%. Why it matters: This research showcases the potential of AI in healthcare to improve cancer diagnosis and treatment, addressing a critical need in resource-constrained healthcare systems.
A KAUST team led by Xin Gao developed an AI model for COVID-19 detection from CT scans, addressing limitations of existing methods. The model incorporates a novel embedding strategy, a CT scan simulator, and a 2.5D deep-learning algorithm. Tested at King Faisal Specialist Hospital, the model demonstrated high accuracy in detecting COVID-19 cases. Why it matters: This research provides a valuable tool for rapid and accurate COVID-19 diagnosis in the region, especially in early-stage infections, improving healthcare outcomes.
KAUST and King Faisal Specialist Hospital and Research Centre (KFSH&RC) are collaborating to develop bioelectronic sensors for rapid pathogen detection. These sensors aim to provide cheap and accurate results, potentially replacing conventional lab tests. A COVID-19 saliva test developed by KAUST researchers showed comparable sensitivity to PCR tests with a 15-minute turnaround. Why it matters: This partnership accelerates the development of novel diagnostic tools, which could improve healthcare accessibility in remote areas and low-income countries within the region.
KAUST's Sciencetown podcast episode 23 features researcher Dana Al-Sulaiman discussing portable biosensing technologies for cancer detection. These devices aim to enable liquid biopsies for early screening and personalized treatment. The biosensors gather clinical information from biological samples to inform clinical decisions. Why it matters: This research can advance non-invasive diagnostics and personalized medicine in the region.
KAUST and Saudi healthtech company amplifAI health have signed an MoU to develop a new disease detection system. The system will combine amplifAI's AI technology with KAUST's HyplexTM hyperspectral imaging, initially for diabetic foot complications. Clinical trials are planned, with aims to reduce amputations and save Saudi Arabia over 2 billion Riyals annually. Why it matters: This partnership showcases the potential of combining Saudi AI and advanced imaging technologies to address pressing healthcare challenges in the region, particularly diabetes.
KAUST researchers developed a statistical approach to improve the identification of cancer-related protein mutations by reducing false positives. The method uses Bayesian statistics to analyze protein domain data from tumor samples, accounting for potential errors due to limited data. The team tested their method on prostate cancer data, successfully identifying a known cancer-linked mutation in the DNA binding protein cd00083. Why it matters: This enhances the reliability of cancer research at the molecular level, potentially accelerating the discovery of new therapeutic targets.